CNBC's David Faber reports Perrigo will reject Mylan's latest offer.» Read More
April 17- Teva Pharmaceuticals Industries is considering a bid for Mylan NV, Bloomberg reported, citing people familiar with the matter. Teva has not made a formal approach, Bloomberg reported. Generic drugmaker Mylan offered to buy Perrigo Co Plc for about $29 billion in cash and stock in early April.
Deals this week, the busiest so far this year, were worth $140 billion, lifting year-to-date M&A activity to almost $1 trillion, according to Thomson Reuters data. It worked for Mylan on its offer for Perrigo, BG Group in its takeover by Shell, TNT Express in its $4.3 billion bid from Fedex and Permira Advisers and the Canada Pension Plan Investment Board in its...
*M&A speculation boosts Burberry, Mediaset. Burberry was flagged by Goldman Sachs among shares on its "conviction buy" lists for which its sees a bid probability of 30 percent or more. Italian media group Mediaset rose 2.2 percent after Mediobanca tipped it as a bid target for France's Vivendi.
*M&A speculation boosts Burberry, Mediaset. Burberry was flagged by Goldman Sachs among shares on its "conviction buy" lists for which its sees a bid probability of 30 percent or more. Italian media group Mediaset rose 2.8 percent after Mediobanca flagged it as a bid target for France's Vivendi.
*Mylan jumps after offering to buy Perrigo for about $29 bln. *Alcoa flat in extended trading after results. NEW YORK, April 8- U.S. stocks ended a volatile session with modest gains on Wednesday after minutes from a U.S.
*Fed minutes indicate rate hike in 2015, but members differ on month. *Mylan jumps after offering to buy Perrigo for about $29 bln. NEW YORK, April 8- U.S. stocks rose on Wednesday, but trading was volatile following the release of minutes from the U.S.
*Mylan jumps after offering to buy Perrigo for about $29 bln. Mylan shares jumped 14.4 percent to $68.15, boosting the Nasdaq and the S&P healthcare sector, on news it offered to buy Perrigo for about $29 billion in cash and stock. Perrigo shares jumped 21.7 percent to $200.50.
Perrigo is set to close a huge deal for Omega Pharmaceuticals. Perrigo CEO Joseph Papa, discusses the benefits of the deal, and the company's move to Ireland.
DUBLIN, Feb 26- Malin, an Irish company set up by a number of former Elan executives to invest in privately held life science assets, said it plans to raise between 275 million and 325 million euros in one of Europe's biggest biotechnology IPOs. Former Elan chief executive Kelly Martin and chairman Bob Ingram, who sold the Irish stock market stalwart to Perrigo for...
Some of the names on the move ahead of the open.
We're moving into a time of year that’s been difficult for bulls, historically. However, if the market does sell off, Cramer won't cry.
The stock market might be making new all-time highs on almost a daily basis, but that doesn’t mean there isn’t bargain to be had.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
U.S. health officials finalized guidelines for infant formula makers that aim to ensure products meet certain quality controls to keep them safe.
Some of Wednesday's midday movers:
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
A couple of stocks stand to gain over the next two weeks, Paul Hickey of Bespoke Investment Group says.
Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?
In his book "Get Rich Carefully," CNBC's "Mad Money" host explains how spotting long-term megatrends can help investors surf the wave of profitability.